Education
About Us
Working with TipRanks
Follow Us
AstraZeneca (AZN)
:AZN
AZN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$61.24 - $87.68
Previous CloseN/A
Volume1.80M
Average Volume (3M)4.96M
Market Cap
$228.65B
Enterprise Value$243.71B
Total Cash (Recent Filing)$7.11B
Total Debt (Recent Filing)$32.84B
Price to Earnings (P/E)27.5
Beta0.31
Next Earnings
Nov 06, 2025EPS Estimate
1.14Next Dividend Ex-Date
Aug 08, 2025Dividend Yield2.08%
Share Statistics
EPS (TTM)1.08
Shares Outstanding3,101,341,300
10 Day Avg. Volume7,407,623
30 Day Avg. Volume4,958,209
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue4.30
Enterprise Value/Gross Profit5.42
Enterprise Value/Ebitda13.10
Forecast
1Y Price Target
$93.00Price Target Upside24.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Oncology Segment PerformanceTotal oncology product sales of $5.854bn beating consensus by ~8%.
Regulatory FilingsRegulatory filings accepted for multiple products in the US, EU, and Japan.
Bears Say
Clinical Trial DiscontinuationThe discontinuation of the CAPItello-280 Ph 3 trial evaluating Truqap in patients with metastatic castration-resistant prostate cancer was announced.
Clinical Trial OutcomesThe clinical program evaluating anselamimab did not achieve statistical significance in the overall population for the primary endpoint.
Sales PerformanceTotal Product Sales of $12,875 bn missing consensus estimates by ~2% and missing Leerink Partners' estimate by ~1%.
AstraZeneca News
AZN FAQ
What was AstraZeneca’s price range in the past 12 months?
AstraZeneca lowest stock price was $61.24 and its highest was $87.67 in the past 12 months.
What is AstraZeneca’s market cap?
AstraZeneca’s market cap is $228.65B.
When is AstraZeneca’s upcoming earnings report date?
AstraZeneca’s upcoming earnings report date is Nov 06, 2025 which is in 92 days.
How were AstraZeneca’s earnings last quarter?
AstraZeneca released its earnings results on Jul 29, 2025. The company reported $1.085 earnings per share for the quarter, beating the consensus estimate of $1.074 by $0.011.
Is AstraZeneca overvalued?
According to Wall Street analysts AstraZeneca’s price is currently Undervalued.
Does AstraZeneca pay dividends?
AstraZeneca pays a Semiannually dividend of $0.505 which represents an annual dividend yield of 2.08%. See more information on AstraZeneca dividends here
What is AstraZeneca’s EPS estimate?
AstraZeneca’s EPS estimate is 1.14.
How many shares outstanding does AstraZeneca have?
AstraZeneca has 3,101,341,300 shares outstanding.
What happened to AstraZeneca’s price movement after its last earnings report?
AstraZeneca reported an EPS of $1.085 in its last earnings report, beating expectations of $1.074. Following the earnings report the stock price went up 2.993%.
Which hedge fund is a major shareholder of AstraZeneca?
Currently, no hedge funds are holding shares in AZN
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$93.00 (24.68% Upside)
$93.00 (24.68% Upside)
Blogger Sentiment
Bullish
AZN Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 8.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.99%
12-Months-Change
Fundamentals
Return on Equity
19.76%
Trailing 12-Months
Asset Growth
7.75%
Trailing 12-Months
Company Description
AstraZeneca
AstraZeneca (AZN) is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company primarily focuses on the discovery, development, and commercialization of prescription medicines in three main therapy areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
AZN Company Deck
AZN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
AstraZeneca's earnings call presented a strong performance with significant revenue and EPS growth, driven by robust demand across oncology and biopharmaceuticals. The company achieved numerous regulatory approvals and positive clinical trial results, indicating a successful pipeline and future growth potential. However, challenges such as the impact of Medicare Part D redesign, Soliris biosimilar competition, and growth rate issues in China were noted. Overall, the positive highlights outweigh the challenges, suggesting a promising outlook.Read More>AZN Stock 12 Month Forecast
Average Price Target
$93.00
▲(24.68%Upside)
Technical Analysis
Ownership Overview
―
Insiders
5.71% Mutual Funds
0.24% Other Institutional Investors
93.11% Public Companies and Individual Investors